GlaxoSmithKline (GS71) Stock Statistics & Valuation Metrics
Total Valuation
GlaxoSmithKline has a market cap or net worth of CHF 80.28B. The enterprise value is CHF 94.96B.
- Market Cap
- CHF 80.28B
- Enterprise Value
- CHF 94.96B
Share Statistics
GlaxoSmithKline has 4,045,439,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,045,439,200
- Owned by Insiders
- 1.14%
- Owned by Institutions
- 27.35%
Financial Efficiency
GlaxoSmithKline’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is 14.25%.
- Return on Equity (ROE)
- 0.35
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 14.25%
- Return on Capital Employed (ROCE)
- 0.18
- Revenue Per Employee
- 488.73K
- Profits Per Employee
- 85.52K
- Employee Count
- 66,841
- Asset Turnover
- 0.53
- Inventory Turnover
- 1.51
Valuation Ratios
The current PE Ratio of GlaxoSmithKline is 16.92. GlaxoSmithKline’s PEG ratio is -0.82.
- PE Ratio
- 16.92
- PS Ratio
- 2.18
- PB Ratio
- 3.91
- Price to FCF
- 10.71
- Price to Operating Cash Flow
- 8.56
- PEG Ratio
- -0.82
Income Statement
In the last 12 months, GlaxoSmithKline had revenue of 32.67B and earned 5.72B in profits. Earnings per share was 1.41.
- Revenue
- 32.67B
- Gross Profit
- 23.70B
- Operating Income
- 7.17B
- Pretax Income
- 7.40B
- Net Income
- 5.72B
- EBITDA
- 11.88B
- Earnings Per Share (EPS)
- 1.41
Cash Flow
In the last 12 months, operating cash flow was 8.56B and capital expenditures -1.72B, giving a free cash flow of 6.84B billion.
- Operating Cash Flow
- 8.56B
- Free Cash Flow
- 6.84B
- Free Cash Flow per Share
- 1.71
Dividends & Yields
GlaxoSmithKline pays an annual dividend of ―, resulting in a dividend yield of 3.66%
- Dividend Per Share
- ―
- Dividend Yield
- 3.66%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 9.34%
- Earnings Yield
- 5.94%
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 26.11
- 200-Day Moving Average
- 26.11
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
GlaxoSmithKline upcoming earnings date is Feb 03, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Oct 28, 2026
- Next Earnings Date
- Feb 03, 2027
- Ex-Dividend Date
- ―
Financial Position
GlaxoSmithKline as a current ratio of 0.82, with Debt / Equity ratio of 108.20%
- Current Ratio
- 0.82
- Quick Ratio
- 0.54
- Debt to Market Cap
- 0.23
- Net Debt to EBITDA
- 1.23
- Interest Coverage Ratio
- 10.23
Taxes
In the past 12 months, GlaxoSmithKline has paid 1.11B in taxes.
- Income Tax
- 1.11B
- Effective Tax Rate
- 0.15
Enterprise Valuation
GlaxoSmithKline EV to EBITDA ratio is 8.83, with an EV/FCF ratio of 13.75.
- EV to Sales
- 2.80
- EV to EBITDA
- 8.83
- EV to Free Cash Flow
- 13.75
- EV to Operating Cash Flow
- 10.99
Balance Sheet
GlaxoSmithKline has CHF 2.96B in cash and marketable securities with CHF 23.70B in debt, giving a net cash position of -CHF 20.74B billion.
- Cash & Marketable Securities
- CHF 2.96B
- Total Debt
- CHF 23.70B
- Net Cash
- -CHF 20.74B
- Net Cash Per Share
- -CHF 5.13
- Tangible Book Value Per Share
- -CHF 3.75
Margins
Gross margin is 73.52%, with operating margin of 23.80%, and net profit margin of 12.97%.
- Gross Margin
- 73.52%
- Operating Margin
- 23.80%
- Pretax Margin
- 16.05%
- Net Profit Margin
- 12.97%
- EBITDA Margin
- 31.72%
- EBIT Margin
- 25.11%
Analyst Forecast
The average price target for GlaxoSmithKline is CHF 22.93, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- CHF 22.93
- Price Target Upside
- 12.19% Downside
- Analyst Consensus
- Neutral
- Analyst Count
- 15
- Revenue Growth Forecast
- 0.46%
- EPS Growth Forecast
- -22.43%
Scores
- Smart Score
- 5
- AI Score
- ―
